Humanetix and BioScience Managers partner to launch tech platform globally
Humanetix is set for global expansion following a partnership with the international investment firm BioScience Managers (BSM).
Humanetix’s main product ACE, is point-of-care documentation, decision-support and clinical workflow IT system that supports staff care delivery for residential aged care residents.
The technology has been part of a 2-year trial conducted by the University of Canberra that showed it can free up 20 per cent of the time nurses and carers spend on paperwork and admin. Watch below ABC news story about the trial conducted at Jindalee Aged Care facility in the ACT.
“Humanetix was born from a need for a clinical management system to improve safety, quality, efficiency and data quality in aged care. With its development funded by the Commonwealth Department of Health, it is a world-first system that the Department has gone on to test and measure through independent research. We are now ready to fly as a globally unique platform delivering proven benefits,” said Inventor, Matt Darling.
“Our new partnership with BioScience Managers will allow us to serve more aged care providers and to innovate into other parts of the health sector – using the same real-time technology to reduce human error, maximise carer time, and remove the end of shift reporting.”
BioScience Managers is investing in Humanetix with the aim to expand across Australia, develop additional platforms to focus on the need of at-home carers and the hospital environment, and take on the global market by targeting the NHS in the UK and regional hospitals across the USA.
“This is an exciting partnership – taking a local and genuinely innovative platform and leveraging our networks and know-how to develop a global footprint that really makes a difference,” said BSM Managing Partner and founder Jeremy Curnock Cook.
BSM is also a fund manager for the Australian Government’s $250M Biomedical Translation Fund (BTF), launched in 2016 and designed to support medical research and commercialisation.